-
公开(公告)号：EP3329965A1
公开(公告)日：2018-06-06
申请号：EP18150968.8
申请日：2012-05-02
发明人： DILUZIO, Willow , TRUONG, Nobel T. , VARGA, Csanad M. , PALANIAPPAN, Vaithianathan , BROWN, Jason , FOX, Irving H. , SCHOLZ, Catherine
CPC分类号： A61K47/26 , A61K9/0019 , A61K9/19 , A61K39/39591 , A61K47/183 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K16/2839 , C07K2317/14 , C07K2317/24 , C07K2317/565 , C07K2317/92 , C07K2317/94
摘要： Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-α4β7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-α4β7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.
-
公开(公告)号：EP4403579A3
公开(公告)日：2024-10-16
申请号：EP24167554.5
申请日：2012-05-02
发明人： DILUZIO, Willow , NGUYEN, Phuong M. , VARGA, Csanad M. , PALANIAPPAN, Vaithianathan , BROWN, Jason , FOX, Irving H. , SCHOLZ, Catherine , JENKINS, Erica Helen , ROSARIO, Maria
摘要： Antibody formulations are described comprising a mixture of an anti-α4β7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.
-
公开(公告)号：EP4378959A3
公开(公告)日：2024-09-04
申请号：EP24167547.9
申请日：2012-05-02
发明人： DILUZIO, Willow , NGUYEN, Phuong M. , VARGA, Csanad M. , PALANIAPPAN, Vaithianathan , BROWN, Jason , FOX, Irving H. , SCHOLZ, Catherine , JENKINS, Erica Helen , ROSARIO, Maria
IPC分类号： A61K39/395 , A61K47/12 , A61K47/14 , A61K47/18 , A61K47/26 , A61K9/00 , A61P1/00 , A61P1/04 , A61P1/16 , A61P1/18 , A61P3/10 , A61P29/00 , A61P31/18 , A61P37/06 , A61P43/00
CPC分类号： A61K9/0019 , A61K47/12 , A61K47/14 , A61K47/183 , A61K47/26 , A61K39/39591 , A61K2039/50520130101 , A61K2039/5420130101 , A61K2039/54520130101 , C07K2317/2420130101 , C07K16/2839 , A61P1/00 , A61P1/04 , A61P1/16 , A61P1/18 , A61P29/00 , A61P31/18 , A61P37/06 , A61P43/00 , A61P3/10
摘要： Antibody formulations are described comprising a mixture of an anti-α4β7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.
-
公开(公告)号：EP4378959A2
公开(公告)日：2024-06-05
申请号：EP24167547.9
申请日：2012-05-02
发明人： DILUZIO, Willow , NGUYEN, Phuong M. , VARGA, Csanad M. , PALANIAPPAN, Vaithianathan , BROWN, Jason , FOX, Irving H. , SCHOLZ, Catherine , JENKINS, Erica Helen , ROSARIO, Maria
IPC分类号： C07K16/28
CPC分类号： A61K9/0019 , A61K47/12 , A61K47/14 , A61K47/183 , A61K47/26 , A61K39/39591 , A61K2039/50520130101 , A61K2039/5420130101 , A61K2039/54520130101 , C07K2317/2420130101 , C07K16/2839 , A61P1/00 , A61P1/04 , A61P1/16 , A61P1/18 , A61P29/00 , A61P31/18 , A61P37/06 , A61P43/00 , A61P3/10
摘要： Antibody formulations are described comprising a mixture of an anti-α4β7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.
-
公开(公告)号：EP2704742A2
公开(公告)日：2014-03-12
申请号：EP12722973.0
申请日：2012-05-02
发明人： DILUZIO, Willow , NGUYEN, Phuong M. , VARGA, Csanad M. , PALANIAPPAN, Vaithianathan , BROWN, Jason , FOX, Irving H. , SCHOLZ, Catherine , JENKINS, Helen , ROSARIO, Maria
CPC分类号： C07K16/2839 , A61K9/0019 , A61K39/39591 , A61K47/12 , A61K47/14 , A61K47/183 , A61K47/26 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/24
摘要： Antibody formulations are described comprising a mixture of an anti-α4β7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.
摘要翻译： 描述了包含抗α4和bgr7抗体，抗氧化剂或螯合剂和至少一种游离氨基酸的混合物的抗体制剂。 所公开的制剂可以具有改善的稳定性，减少的聚集体形成或两者。 本发明进一步提供了易于遵循的这些抗体制剂的安全给药方案，并且其在体内导致治疗有效量的抗α4和bgr7抗体。
-
公开(公告)号：EP4438625A2
公开(公告)日：2024-10-02
申请号：EP24167555.2
申请日：2012-05-02
发明人： DILUZIO, Willow , NGUYEN, Phuong M. , VARGA, Csanad M. , PALANIAPPAN, Vaithianathan , BROWN, Jason , FOX, Irving H. , SCHOLZ, Catherine , JENKINS, Erica Helen , ROSARIO, Maria
IPC分类号： C07K16/28
CPC分类号： A61K9/0019 , A61K47/12 , A61K47/14 , A61K47/183 , A61K47/26 , A61K39/39591 , A61K2039/50520130101 , A61K2039/5420130101 , A61K2039/54520130101 , C07K2317/2420130101 , C07K16/2839 , A61P1/00 , A61P1/04 , A61P1/16 , A61P1/18 , A61P29/00 , A61P31/18 , A61P37/06 , A61P43/00 , A61P3/10
摘要： Antibody formulations are described comprising a mixture of an anti-α4β7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.
-
公开(公告)号：EP3329965A3
公开(公告)日：2018-12-12
申请号：EP18150968.8
申请日：2012-05-02
发明人： DILUZIO, Willow , TRUONG, Nobel T. , VARGA, Csanad M. , PALANIAPPAN, Vaithianathan , BROWN, Jason , FOX, Irving H. , SCHOLZ, Catherine
CPC分类号： A61K47/26 , A61K9/0019 , A61K9/19 , A61K39/39591 , A61K47/183 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K16/2839 , C07K2317/14 , C07K2317/24 , C07K2317/565 , C07K2317/92 , C07K2317/94
摘要： Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-α4β7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-α4β7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.
-
公开(公告)号：EP2704798A2
公开(公告)日：2014-03-12
申请号：EP12721093.8
申请日：2012-05-02
发明人： DILUZIO, Willow , TRUONG, Nobel T. , VARGA, Csanad M. , PALANIAPPAN, Vaithianathan , BROWN, Jason , FOX, Irving H. , SCHOLZ, Catherine
IPC分类号： A61P1/00 , A61K39/395 , C07K16/28
CPC分类号： A61K47/26 , A61K9/0019 , A61K9/19 , A61K39/39591 , A61K47/183 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K16/2839 , C07K2317/14 , C07K2317/24 , C07K2317/565 , C07K2317/92 , C07K2317/94
摘要： Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-α4β7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-α4β7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.
摘要翻译： 描述了包含非还原糖，抗α4和bgr7抗体和至少一种氨基酸的混合物的抗体制剂。 所公开的制剂具有改善的稳定性，减少的聚集体形成，并且可以阻止其中抗α4和bgr7抗体的降解或显示其任何组合。 本发明进一步提供了易于遵循的这些抗体制剂的安全给药方案，并且其在体内导致治疗有效量的抗α4和bgr7抗体。
-
公开(公告)号：EP4378484A3
公开(公告)日：2024-09-04
申请号：EP24167556.0
申请日：2012-05-02
发明人： DILUZIO, Willow , TRUONG, Nobel T. , VARGA, Csanad M. , PALANIAPPAN, Vaithianathan , BROWN, Jason , FOX, Irving H. , SCHOLZ, Catherine
IPC分类号： C07K16/28 , A61K47/18 , A61K39/00 , A61P1/00 , A61K39/395 , A61K9/19 , A61K47/26 , A61K9/00 , A61P1/04 , A61P29/00 , A61P37/00 , A61P37/02
CPC分类号： A61K2039/50520130101 , A61K2039/5420130101 , A61K2039/54520130101 , C07K2317/2420130101 , C07K2317/56520130101 , A61K9/0019 , A61K9/19 , C07K2317/9420130101 , A61K39/39591 , C07K2317/9220130101 , C07K16/2839 , A61K47/183 , A61K47/26 , A61P1/00 , A61P1/04 , A61P29/00 , A61P37/00 , A61P37/02 , A61K39/395
摘要： Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-α4β7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-α4β7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.
-
公开(公告)号：EP4403579A2
公开(公告)日：2024-07-24
申请号：EP24167554.5
申请日：2012-05-02
发明人： DILUZIO, Willow , NGUYEN, Phuong M. , VARGA, Csanad M. , PALANIAPPAN, Vaithianathan , BROWN, Jason , FOX, Irving H. , SCHOLZ, Catherine , JENKINS, Erica Helen , ROSARIO, Maria
IPC分类号： C07K16/28
CPC分类号： A61K9/0019 , A61K47/12 , A61K47/14 , A61K47/183 , A61K47/26 , A61K39/39591 , A61K2039/50520130101 , A61K2039/5420130101 , A61K2039/54520130101 , C07K2317/2420130101 , C07K16/2839 , A61P1/00 , A61P1/04 , A61P1/16 , A61P1/18 , A61P29/00 , A61P31/18 , A61P37/06 , A61P43/00 , A61P3/10
摘要： Antibody formulations are described comprising a mixture of an anti-α4β7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.
-
-
-
-
-
-
-
-
-
搜索结果
15 条记录 (耗时 0.014 秒)
